Rose Research Center

Executive Summary

Rose Research Center, established in 1995 and headquartered in Miami, Florida, is a specialized clinical research organization with a strong focus on tobacco dependence, addiction, smoking cessation, and tobacco harm reduction. With over two decades of experience, the center operates multiple well-equipped offices staffed with dedicated professionals and advanced technology to conduct a broad spectrum of study protocols. Its expertise spans research on smokers, addiction mechanisms, and evaluation of alternative tobacco products, positioning it as a key player in the public health effort to reduce smoking-related harm. The center collaborates with academic institutions, government agencies, and industry partners to generate robust evidence that informs regulatory decisions and clinical practice. As a privately held entity, Rose Research Center has maintained a steady presence in the competitive clinical research landscape. Its focus on tobacco and nicotine products aligns with evolving regulatory frameworks, such as FDA oversight of modified risk tobacco products. The center's long history and specialized capabilities make it a valuable partner for studies requiring deep expertise in addiction and behavioral interventions. While not a publicly traded company, its impact is measured through scientific contributions and influence on public health policies. The center is well-positioned to benefit from increased research funding and regulatory interest in harm reduction strategies.

Upcoming Catalysts (preview)

• Q2 2026Announcement of new NIH or FDA grant for tobacco harm reduction research70% success
• Q4 2026Publication of landmark study on e-cigarette cessation efficacy60% success
• Q1 2027Partnership with major pharmaceutical company for smoking cessation drug trial50% success